ストックスクリーナーアプリを入手
110.08
0.93%
-1.03
Gilead Sciences Inc (GILD) 最新ニュース
Gilead Sciences (GILD) Reports Positive Results for Trodelvy Com - GuruFocus
Gilead’s Trodelvy with Keytruda cuts breast cancer risk (GILD) - Seeking Alpha
Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial - Yahoo
Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold? - The Globe and Mail
Gilead Eyes HIV Drug Rollout In Low-Income Countries Despite Funding Uncertainty, Says Report: Retail Holds Onto Bearish Stance By Stocktwits - Investing.com India
Transforming How Cancer Is Treated: Research Results To Be Shared at ASCO25 - CSRwire
Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty - Reuters
Gilead Sciences Plans to Supply Twice-Yearly HIV Prevention Shot to Low-Income Countries Pending FDA Approval - geneonline.com
Gilead Sciences Commemorated the Opening of the Bay Area Young Survivors Breast Cancer Memorial Garden - ACCESS Newswire
Gilead at Bernstein Conference: Strategic Growth and Innovation - Investing.com
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Gilead at Bernstein Conference: Strategic Growth and Innovation By Investing.com - Investing.com UK
Transcript : Gilead Sciences, Inc. Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-29-2025 02 - marketscreener.com
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock - Yahoo Finance
Gilead Sciences and Kite Pharma To Announce Transformative - CSRwire
Gilead Sciences’ SWOT analysis: HIV giant faces oncology growth, patent cliff - Investing.com Nigeria
ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs - insights.citeline.com
Gilead Ready To Go After Hepatitis D Again - insights.citeline.com
Gilead Sciences' Best Days May Be AheadHere's Why (NASDAQ:GILD) - Seeking Alpha
GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer - Yahoo Finance
Gilead’s Phase III trial for breast cancer therapy meets primary goal - Clinical Trials Arena
Gilead Sciences, Inc. (GILD)’s Breast Cancer Study Success Drives Investor Optimism Amid Broader Market Slump - MSN
Gilead says Trodelvy ASCENT-03 study meets primary endpoint - The Pharma Letter
Gilead announces ASCENT-03 study meets primary endpoint - Yahoo Finance
Gilead Sciences (NasdaqGS:GILD) Announces Promising Phase 3 Results For Trodelvy In Breast Cancer - simplywall.st
Gilead (GILD) to Acquire HOOK for $10 million - Insider Monkey
Gilead Sciences (GILD) Achieves Key Trial Milestone with Trodelv - GuruFocus
After Keytruda combo win, Gilead's Trodelvy meets the mark in solo breast cancer trial - Fierce Pharma
Gilead (GILD) Announces Promising Results from Trodelvy Study | - GuruFocus
Gilead Sciences Says Trodelvy Met Primary Endpoint in Phase 3 Breast Cancer Trial - marketscreener.com
Gilead posts trial win for Trodelvy in breast cancer (GILD) - Seeking Alpha
Gilead (GILD) Announces Promising Results from Trodelvy Study | GILD Stock News - GuruFocus
ASCENT-03Trodelvy Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors - marketscreener.com
Gilead Sciences (GILD) announces positive data from Phase 3 Trodelvy study - StreetInsider
ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors - Business Wire
Gilead records another pivotal study success for Trodelvy in first-line TNBC - FirstWord Pharma
Sector Update: Health Care Stocks Softer Late Afternoon - marketscreener.com
Sector Update: Health Care Stocks Retreat Thursday Afternoon - marketscreener.com
HOOKIPA to Sell HBV, HIV Program Assets to Gilead; Shares Rise - marketscreener.com
Gilead (GILD) Experiences Significant Increase in Bearish Options Activity | GILD Stock News - GuruFocus
Gilead Sciences to Acquire HOOKIPA Pharma Assets for $10M - GuruFocus
Hookipa stock gains as Gilead eyes assets (HOOK:NASDAQ) - Seeking Alpha
Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs - Fierce Biotech
Hookipa Pharma Sells Assets to Gilead Sciences - TipRanks
What Analysts Are Saying About Gilead Sciences Stock - Benzinga
Tomas Cihlar, Gilead Sciences, Named to TIME’s List of 100 Most Influential People in the World for HIV Research - CSRwire
Here's Why Gilead Sciences (GILD) is a Strong Value Stock - Yahoo Finance
Gilead Sciences (GILD) Receives Hold Rating from Needham | GILD Stock News - GuruFocus
0.17%
大文字化:
|
ボリューム (24 時間):